Literature DB >> 6313359

Relation between beta-lactamase production and antimicrobial activity: comparison of the new compound HR 810 with cefotaxime.

W Cullmann, W Opferkuch, M Stieglitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6313359     DOI： 10.1007/bf02019466

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN： 0722-2211            Impact factor:   3.267


× No keyword cloud information.
  6 in total

1.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.

Authors:  M A Markwell; S M Haas; L L Bieber; N E Tolbert
Journal:  Anal Biochem       Date:  1978-06-15       Impact factor: 3.365

2.  The interaction of beta-lactam compounds with chromosomally mediated enzymes: relations to the molecular structure.

Authors:  W Cullmann
Journal:  Chemotherapy       Date:  1985       Impact factor: 2.544

3.  Interaction of mezlocillin and cefoxitin against Proteus morganii in the granuloma pouch model.

Authors:  A Dalhoff
Journal:  Eur J Clin Microbiol       Date:  1982-08       Impact factor: 3.267

4.  Novel resistance selected by the new expanded-spectrum cephalosporins: a concern.

Authors:  C C Sanders
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

5.  In vitro evaluation of CENTA, a new beta-lactamase-susceptible chromogenic cephalosporin reagent.

Authors:  R N Jones; H W Wilson; W J Novick; A L Barry; C Thornsberry
Journal:  J Clin Microbiol       Date:  1982-05       Impact factor: 5.948

6.  Properties of Ro 13-99041 as a substrate and inhibitor of beta-lactamases.

Authors:  R L Then
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544
  6 in total
  10 in total

1.  In vitro activity of HR 810, a new cephalosporin.

Authors:  M A Bertram; D A Bruckner; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

2.  Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacy.

Authors:  D J Phelps; D D Carlton; C A Farrell; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

3.  In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin.

Authors:  R N Jones; C Thornsberry; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

4.  In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.

Authors:  A Tsuji; A Maniatis; M A Bertram; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

5.  In vitro antimicrobial activity of cefpirome against ceftazidime-resistant isolates from two multicenter studies.

Authors:  H S Sader; R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-08       Impact factor: 3.267

6.  Anti-pseudomonal activity of HR 810.

Authors:  M O Husson; D Izard; A Bryskier; H Leclerc
Journal:  Infection       Date:  1985 Mar-Apr       Impact factor: 3.553

7.  Beta-lactamase stability of cefpirome (HR 810), a new cephalosporin with a broad antimicrobial spectrum.

Authors:  S Kobayashi; S Arai; S Hayashi; K Fujimoto
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

8.  In vitro activity of HR 810, a new broad-spectrum cephalosporin.

Authors:  K Machka; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

9.  Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories.

Authors:  R N Jones; C Thornsberry; A L Barry; L Ayers; S Brown; J Daniel; P C Fuchs; T L Gavan; E H Gerlach; J M Matsen
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

10.  Interaction of cefpirome and a cephalosporinase from Citrobacter freundii GN7391.

Authors:  S Satake; M Hiraoka; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.